Sands Capital Ventures
SGP icon

Sands Capital Ventures’s SpyGlass Pharma SGP Stock Holding History

Sands Capital Ventures’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$65M Hold
2,500,012
– – 9.36% 4
2026
Q2 		$55.7M Hold
2,500,012
– – 9.07% 5
2026
Q1 		$64.8M Buy
+2,500,012
New +$67.3M 15.38% 3

Other funds holding SGP

JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $116B AUM 33.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Sands Capital Ventures's SGP Position: Q3 2026 in Review

Sands Capital Ventures held its SpyGlass Pharma (SGP) position steady in Q3 2026 at 2,500,012 shares worth $65M. The position accounts for 9.36% of the portfolio, ranked #4.

Sands Capital Ventures first reported a position in SGP in Q1 2026 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold SGP as of Q3 2026.

  • Sands Capital Ventures held 2,500,012 shares of SpyGlass Pharma worth $65M as of Q3 2026.
  • Sands Capital Ventures left its SpyGlass Pharma share count unchanged in Q3 2026.
  • SpyGlass Pharma made up 9.36% of Sands Capital Ventures's portfolio in Q3 2026, its #4 holding.
  • Sands Capital Ventures first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 3 quarters since.
  • 47 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q3 2026.

Based on Sands Capital Ventures's 13F filing for Q3 2026, filed 13 Nov 2026.